


Product Information



Borrelidin

Item No. 14436

CAS Registry No.: 7184-60-3
Formal Name: (1R)-2R-[7-cyano-8R,16S-dihydroxy-9S,11R,13S,15S-tetramethyl-18-oxooxacyclooctadeca-4E,6Z-dien-2S-yl]-cyclopentanecarboxylic acid
Synonyms: NSC 216128, Treponemycin
MF: C₂₈H₄₃NO₆
FW: 489.6
Purity: ≥98%
Stability: ≥1 year at -20°C
Supplied as: A white to off-white powder



Laboratory Procedures

For long term storage, we suggest that borrelidin be stored as supplied at -20°C. It should be stable for at least one year. Borrelidin is supplied as a white to off-white powder. A stock solution may be made by dissolving the borrelidin in the solvent of choice. Borrelidin is soluble in organic solvents such as methanol and DMSO.

Borrelidin is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Borrelidin is a secondary metabolite produced by *Streptomyces* and other bacteria. It displays potent antiangiogenic activity, preventing tube formation in rat aorta explants (IC₅₀ = 0.8 nM) and inducing apoptosis in endothelial cells.^{1,2} Borrelidin also alters the splicing of VEGF mRNA, producing an antiangiogenic isoform of the growth factor.³ It has long been known as a powerful inhibitor of both eukaryotic and bacterial threonyl tRNA synthetase.⁴ Borrelidin is also an effective anti-malarial drug, as it kills *P. falciparum* with an IC₅₀ value of 1.8 nM.⁵ At higher doses, it inhibits cyclin-dependent kinase in yeast (IC₅₀ = 24 μM), resulting in growth arrest in the G₁ phase.⁶

References

1. Wakabayashi, T., Kageyama, R., Naruse, N., *et al.* Borrelidin is an angiogenesis inhibitor; Disruption of angiogenic capillary vessels in a rat aorta matrix culture model. *J. Antibiot.* **50(8)**, 671-676 (1997).
2. Kawamura, T., Liu, D., Towle, M.J., *et al.* Anti-angiogenesis effects of borrelidin are mediated through distinct pathways: Threonyl-tRNA synthetase and caspases are independently involved in suppression of proliferation and induction of apoptosis in endothelial cells. *J. Antibiot.* **56(8)**, 709-715 (2003).
3. Woolard, J., Vousden, W., Moss, S.J., *et al.* Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms. *Chem. Sci.* **2011(2)**, 273-278 (2011).
4. Paetz, W. and Nass, G. Biochemical and immunological characterization of threonyl-tRNA synthetase of two borrelidin-resistant mutants of *Escherichia coli* K12. *Eur. J. Biochem.* **35**, 331-337 (1973).
5. Otoguro, K., Ui, H., Ishiyama, A., *et al.* *In vitro* and *in vivo* antimalarial activities of a non-glycosidic 18-membered macrolide antibiotic, borrelidin, against drug-resistant strains of *Plasmodia*. *J. Antibiot.* **56(8)**, 727-729 (2003).
6. Tsuchiya, E., Yukawa, M., Miyakawa, T., *et al.* Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of *Saccharomyces cerevisiae*. *J. Antibiot.* **54(1)**, 84-90 (2001).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/14436

Cayman Chemical

Mailing address
1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone
(800) 364-9897
(734) 971-3335

Fax
(734) 971-3640

E-Mail
custserv@caymanchem.com

Web
www.caymanchem.com

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 01/22/2014